Jessica Davis is Associate Editor of Healthcare IT News.
By Jessica Davis 04:21 pm June 28, 2017
By adding a local, read-only file, users can block a potential Petya attack. But unlike WannaCry, researchers haven’t found a permanent way to stop the spread of the virus.
By Jessica Davis 11:52 am June 28, 2017
Company says at least a portion of the infections stemmed from a software supply-chain attack with a legitimate MEDoc updater process.
By Jessica Davis 10:31 am June 28, 2017
The major voice and language tool provider joins the 64 countries hit by the virus, as well as global pharma giant Merck and a health system in Pennsylvania.
By Jessica Davis 03:18 pm June 27, 2017
Expressing concerns about risks related to cost and implementation delays, three Republican senators pressed the agencies for assurances the new platforms will be interoperable.
By Jessica Davis 12:17 pm June 27, 2017
The virulent Petya strain spread by infected email attachments that can reboot and shutdown computers, is wreaking havoc across the globe. The networks of global pharma giant Merck were compromised in the attack, as well as a Pennsylvania-based health system.
By Jessica Davis 04:15 pm June 26, 2017
While the group’s CTO Wayne Kubick supports the move from an outdated, custom platform to a commercial EHR, organizations don’t need to be on the same platform to be interoperable, he said.
By Jessica Davis 02:35 pm June 26, 2017
Limitations in its data system prevent metrics from capturing all provider types and provider workload – among other technical and policy flaws.
By Jessica Davis 11:45 am June 26, 2017
Airway Oxygen discovered the breach in April when a hacker gained access to the network.
By Jessica Davis 01:57 pm June 22, 2017
It appears the hackers rushed the latest round of the notorious ransomware, since the campaign is currently only able to lock down XP, VistA and other older operating systems.
By Jessica Davis 04:51 pm June 21, 2017
The lawsuit filed by D.C. attorneys Boyden Gray and Adam Waldman alleges the biotech mogul is seeking to acquire Altor Bioscience through a sweetheart deal.